Biogen has finalized its acquisition of Apellis Pharmaceuticals, gaining full ownership of two commercial products, EMPAVELI® and SYFOVRE®, which generated $689 million in revenue in 2025. This deal enhances Biogen's growth prospects and expands its presence in nephrology, with plans to launch felzartamab after a Phase 3 trial readout expected in early 2027. The acquisition is expected to increase Biogen's earnings per share starting in 2027 and improve its long-term financial outlook. Updated financial guidance will be shared with Biogen's Q2 earnings report in July.
Biogen reported Phase 2 trial results for diranersen, a tau-targeting therapy for early Alzheimer’s, showing cognitive benefits and reduced tau biomarkers despite missing the primary endpoint. The drug slowed cognitive decline across doses, especiall...
Biogen announced positive topline results from its Phase 2 CELIA study of diranersen, an investigational therapy targeting tau protein in early Alzheimer's disease. The study showed robust reductions in tau pathology and a slowing of cognitive declin...
